Arbutus Biopharma Corporation
ABUSNASDAQHealthcare● Active
$4.29
+$0.05(+1.06%)
Market Cap$846449087
P/E Ratio—
52W High$5.1
52W Low$3.04
Arbutus Biopharma Corporation (ABUS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABUS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($33.50M) | ($69.92M) | ($72.85M) | ($69.46M) | ($76.25M) |
| Depreciation & Amort. | $0.36M | $1.38M | $1.40M | $1.43M | $1.75M |
| Stock-Based Comp. | $6.95M | $8.99M | $9.30M | $7.18M | $6.42M |
| Change in Working Capital | ($10.02M) | ($2.83M) | ($18.23M) | $29.24M | $0.93M |
| Net Cash from Operations | ($39.64M) | ($64.85M) | ($85.94M) | ($35.36M) | ($67.53M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | ($0.18M) | ($1.01M) | ($0.51M) | ($0.81M) |
| Purchases of Investments | $12.87M | ($141.51M) | ($80.51M) | ($130.43M) | ($82.22M) |
| Sales of Investments | $155.28M | $164.64M | $132.27M | $56.00M | $70.35M |
| Net Cash from Investing | $15.58M | $22.95M | $50.77M | ($74.94M) | ($12.68M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | ($12.14M) |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $5.72M | $52.00M | $30.65M | $31.81M | $137.24M |
| Free Cash Flow | |||||
| Free Cash Flow | ($39.64M) | ($65.03M) | ($86.94M) | ($35.87M) | ($68.34M) |
| FCF Margin %(computed) | -281.45% | — | -479.27% | -91.92% | -621.96% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Arbutus Biopharma Corporation data
About Arbutus Biopharma Corporation (ABUS) Cash Flow Statement
Arbutus Biopharma Corporation generated operating cash flow of ($0.04B) and free cash flow of ($0.04B) for 2025 — a FCF margin of -281.45%. Capital expenditure was $0.00B.
Frequently asked questions
ABUS · 4 questionsArbutus Biopharma Corporation generated free cash flow of ($0.04B) for 2025, up 39.1% year-over-year.
ABUS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10